Medicure Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Albert D. Friesen
- Full Time Employees
- 22
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 2-1250 Waverley Street Winnipeg MB Canada R3T 6C6
- IPO Date
- Mar 30, 1999
- Website
- medicure.com
- Similar Companies
- Business
- Medicure Inc. (TSXV:MPH) is a biopharmaceutical company focused on the research, development, commercialization, and distribution of cardiovascular therapeutics primarily in the United States through its subsidiary Medicure Pharma Inc.; core products include AGGRASTAT (tirofiban hydrochloride) injection, a glycoprotein GP IIb/IIIa receptor antagonist for acute coronary syndrome including unstable angina/non-Q-wave myocardial infarction; ZYPITAMAG (pitavastatin) tablets, an HMG-CoA reductase inhibitor for primary hyperlipidemia or mixed dyslipidemia; and BRENZAVVY, marketed through direct-to-consumer pharmacy operations including Marley Drug Inc.; the company also advances pipeline candidates such as Sodium Nitroprusside injection, generic ANDAs for acute cardiology, and TARDOCAL for neurological indications, with products distributed via retail, mail-order pharmacies, and its expanding owned pharmacies. Founded in 1997 and headquartered in Winnipeg, Manitoba, Canada, Medicure operates manufacturing facilities in New Jersey and India while targeting U.S. hospital, retail, and direct-to-patient markets to address unmet needs in cardiovascular care. Recent strategic expansions include the February 2025 acquisition of Gateway Medical Pharmacy adding approximately $3.1 million in annual revenue and $271,000 net profit, followed by the April 2025 agreement and June 2025 closing of West Olympia Pharmacy for $975,000 cash, contributing $6.8 million revenue and $325,000 net income for the year ended December 31, 2024, to accelerate ZYPITAMAG and other product growth, enhance patient adherence, reduce distribution costs, and build a $10 million annual net revenue pharmacy segment.
Company News
Medicure (OTCMKTS:MCUJF) Share Price Breaks Above 50-Day Moving Average – What’s Next?
Medicure (OTCMKTS:MCUJF) Shares Break Above 50-Day Moving Average – Time to Sell?
Medicure Announces Grant of Stock Options
Medicure Announces Completion of Enrollment in Its MEND-PNPO Phase 3 Clinical Trial
Medicure (OTCMKTS:MCUJF) Shares Cross Above 50-Day Moving Average – Should You Sell?
Medicure Presents MEND-PNPO Phase 3 Study Design and Baseline Data at the 16th European Epilepsy Congress
Medicure Inc. (MPH:CA) Q2 2026 Earnings Call Prepared Remarks Transcript
Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call
Comparing Medicure (OTCMKTS:MCUJF) & Takeda Pharmaceutical (NYSE:TAK)
Medicure Announces CFO Change
Medicure Inc. (MPH:CA) Q1 2026 Earnings Call Prepared Remarks Transcript
Medicure Announces AGM Results and Appointment of New Director
Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call
Medicure Inc. (MPH:CA) Q4 2025 Earnings Call Prepared Remarks Transcript
Medicure (OTCMKTS:MCUJF) and Wellgistics Health (NASDAQ:WGRX) Head to Head Analysis
Medicure Announces Resignation of President and Chief Operating Officer
Medicure (OTCMKTS:MCUJF) Share Price Crosses Above 50 Day Moving Average – Here’s Why
Medicure Inc. (MPH:CA) Q3 2025 Earnings Call Transcript
Medicure Reports Financial Results for Quarter Ended September 30, 2025
Medicure To Present Financial Results on November 20, 2025 Call at 8:30 AM ET for Quarter Ended September 30, 2025